Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis

Launched by TUBERCULOSIS RESEARCH CENTRE, INDIA · Jun 16, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how COVID-19 (caused by the SARS-CoV-2 virus) affects people who have pulmonary tuberculosis (TB). Researchers want to understand how having both infections might change the way the immune system works, how severe the diseases are, and how well treatments for TB work in these patients. They believe that if someone has had COVID-19, even without symptoms, it could impact their immune response and treatment outcomes for TB. The trial will look at blood samples to see how immune cells respond at the beginning of treatment and after two months of treatment, as well as other important factors related to the diseases.

To participate in the study, individuals must be between 18 and 65 years old and have a new diagnosis of TB, with or without a current or past COVID-19 infection. They should not have had TB before or be currently receiving treatment for it. Participants will need to give written consent to join the study. Throughout the trial, participants can expect to provide blood samples and undergo some tests that will help researchers better understand the relationship between TB and COVID-19. This research could ultimately help improve treatment strategies for patients dealing with both illnesses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age group 18-65;
• • Newly diagnosed smear or GeneXpert positive for TB with or without SARS-CoV-2 (present or prior asymptomatic) disease;
• • Willing to provide written informed consent.
• Exclusion Criteria:
• • Any prior episode of TB disease;
• • Treatment for current TB episode \>1 week before enrollment;
• • Drug resistance TB patients;
• • Pregnancy or childbirth within last 6 months;
• • Diabetes, HIV-seropositive and current use of immunosuppressive and steroid therapy Mild, Moderate and severe Covid-19 disease.